{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:39:45Z","timestamp":1793108385597,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:p>\n                    Although transplantation remains the treatment of choice for end-stage renal disease, patients suffering from severe obesity are too often unlisted for this reason. Pre-transplant bariatric surgery is not free of risk and the use of \u2018Glucagon Like Peptide-1\u2019analogues in these patients is limited. Our study aims to determine whether semaglutide administration enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates. Between 01\/01\/2021 and 10\/30\/2023, patients rejected from renal transplantation because of obesity received pre-transplant subcutaneous semaglutide up to 1\u2005mg\/week. Of the 23 patients included, initial mean body weight, BMI and waist circumference were 102.9\u2005Kg, 35.6 and 119.5\u2005cm respectively. After a median of 12.2 months on semaglutide, these parameters decreased by 11.4\u2005Kg (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.001), 3.9 points (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.001) and 9.6\u2005cm (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.001) respectively. 56.5% of patients initially rejected for transplantation were listed within a median of 5.4 months, and 61.5% of them were transplanted. No major side effects were reported. In summary semaglutide administration enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates. This treatment should be an integral part of the pre-transplant management of obesity.\n                  <\/jats:p>","DOI":"10.3389\/frtra.2025.1623096","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:18:11Z","timestamp":1761743891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Elective semaglutide prescription enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates"],"prefix":"10.3389","volume":"4","author":[{"given":"Emilie","family":"Navaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Huberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Mourabit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Caes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Koliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Mikhalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Le Moine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","article-title":"Obesity and overweight","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12882-021-02278-1","article-title":"Renal transplantation outcomes in obese patients: a French cohort-based study","volume":"22","author":"Foucher","year":"2021","journal-title":"BMC Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/osp4.629","article-title":"Obesity and chronic kidney disease: a current review","volume":"9","author":"Nawaz","year":"2023","journal-title":"Obes Sci Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","article-title":"Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients","volume":"63","author":"Kalantar-Zadeh","year":"2003","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100568","DOI":"10.1016\/j.xkme.2022.100568","article-title":"Prevalence of obesity and CKD among adults in the United States, 2017\u20132020","volume":"5","author":"Friedman","year":"2023","journal-title":"Kidney Med"},{"key":"B6","article-title":"Mortality after initiation of dialysis, 2007, 2012, 2017 and 2019","year":"2024"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10730","DOI":"10.1038\/s41598-023-37814-6","article-title":"Healthcare costs after kidney transplantation compared to dialysis based on propensity score methods and real world longitudinal register data from Sweden","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1159\/000345476","article-title":"Obesity and kidney transplant candidates: how big is too big for transplantation?","volume":"36","author":"Lentine","year":"2012","journal-title":"Am J Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.transproceed.2014.09.112","article-title":"Outcomes in obese kidney transplant recipients","volume":"46","author":"Gusukuma","year":"2014","journal-title":"Transplant Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"B12","volume-title":"Glucagon-Like Peptide-1 Receptor Agonists","author":"Collins","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2005mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/nep.14277","article-title":"Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease","volume":"29","author":"Wallace","year":"2024","journal-title":"Nephrology (Carlton"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/ckj\/sfac090","article-title":"Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?","volume":"15","author":"Touzot","year":"2022","journal-title":"Clin Kidney J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/dc12-1452","article-title":"Measurement of waist circumference: midabdominal or iliac crest?","volume":"36","author":"Ma","year":"2013","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.34067\/kid.0001682022","article-title":"Guiding kidney transplantation candidates for effective weight loss: a clinical cohort study","volume":"3","author":"Kukla","year":"2022","journal-title":"Kidney360"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100388","DOI":"10.1016\/j.xkme.2021.09.005","article-title":"Weight loss challenges in achieving transplant eligibility in patients with kidney failure: a qualitative study","volume":"4","author":"Freeman","year":"2022","journal-title":"Kidney Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1600-6143.2012.04323.x","article-title":"Quantification of the early risk of death in elderly kidney transplant recipients","volume":"13","author":"Gill","year":"2013","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/j.1600-6143.2010.03330.x","article-title":"Body mass index, waist circumference and mortality in kidney transplant recipients","volume":"10","author":"Kovesdy","year":"2010","journal-title":"Am J Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41598-020-80266-5","article-title":"Impact of changes in waist-to-hip ratio after kidney transplantation on cardiovascular outcomes","volume":"11","author":"Gwon","year":"2021","journal-title":"Sci Rep (London England)"},{"key":"B25","article-title":"Arr\u00eat\u00e9 royal prolongeant l'arr\u00eat\u00e9 royal du 9 novembre 2023 fixant les conditions de prescription et de d\u00e9livrance des m\u00e9dicaments appartenant aux analogues GLP-1 qui font l'objet d'une autorisation comptant l'indication du diab\u00e8te type 2 mellitus","year":"2025"},{"key":"B26","volume-title":"Centre Belge D'Information Pharmacoth\u00e9rapeutique (CBIP)","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1056\/NEJMc2407932","article-title":"Fair allocation of GLP-1 and dual GLP-1-GIP receptor agonists. Reply","volume":"391","author":"Persad","year":"2024","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/asn.2007050610","article-title":"Obesity impacts access to kidney transplantation","volume":"19","author":"Segev","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jacc.2008.12.040","article-title":"Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease","volume":"53","author":"Postorino","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.12659\/aot.892067","article-title":"Waist circumference as an independent risk factor for NODAT","volume":"20","author":"Dedinsk\u00e1","year":"2015","journal-title":"Ann Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"Maciejewski","year":"2016","journal-title":"JAMA Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1623096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:18:12Z","timestamp":1761743892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1623096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":33,"alternative-id":["10.3389\/frtra.2025.1623096"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2025.1623096","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1623096"}}